{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:49Z","timestamp":1790613769964,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CLIN INFECT DIS"],"published-print":{"date-parts":[[2003,1,15]]},"DOI":"10.1086\/345744","type":"journal-article","created":{"date-parts":[[2003,1,20]],"date-time":"2003-01-20T15:20:42Z","timestamp":1043076042000},"page":"159-168","source":"Crossref","is-referenced-by-count":346,"title":["Linezolid for the Treatment of Multidrug\u2010Resistant, Gram\u2010Positive Infections: Experience from a Compassionate\u2010Use Program"],"prefix":"10.1093","volume":"36","author":[{"given":"Mary C.","family":"Birmingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison K.","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Flavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald H.","family":"Batts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome J.","family":"Schentag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"rf1_160","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)11192-2"},{"key":"rf2_161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400701"},{"key":"rf3_162","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.3.430-438.2002"},{"key":"rf4_163","first-page":"565","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"rf5_164","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/AAC.40.3.720","volume":"40","author":"Jones RN","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"rf6_165","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(91)90002-W"},{"key":"rf7_166","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","volume":"40","author":"Zurenko GE","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"rf8_167","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","volume":"40","author":"Kaatz GW","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"rf9_168","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","volume":"41","author":"Shinabarger DL","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"rf10_169","first-page":"23","author":"Stalker DJ","year":"1997","journal-title":"DC: American Society for Microbiology"},{"key":"rf11_170","unstructured":"Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:23."},{"key":"rf12_171","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.255"},{"key":"rf13_172","first-page":"1014","volume":"28","author":"Wynalda MA","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"rf14_173","first-page":"1136","volume":"29","author":"Slatter JG","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"rf15_174","unstructured":"Dresser LD, Birmingham MC, Karchmer AW, Rayner CR, Falvin SM, Schentag JJ. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5."},{"key":"rf16_175","unstructured":"Zurenko GE, Todd WM, Hafkin B, etal Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1997:118."},{"key":"rf17_176","unstructured":"Lee JC, Zurenko GE, Shinabarger DI, Cammarata SK. Factors which may influence development of clinical resistance to linezolid in enterococcal species [abstract 531]. In: Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001:1179."},{"key":"rf18_177","unstructured":"Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical modelling of hematologic effects of linezolid (L) in seriously-ill patients (pts) [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5."},{"key":"rf19_178","doi-asserted-by":"publisher","DOI":"10.1086\/340353"},{"key":"rf20_179","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.263.34198"},{"key":"rf21_180","unstructured":"Zyvox [package insert]. Kalamazoo, Michigan: Pharmacia, 2001."},{"key":"rf22_181","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2723-2726.2002"},{"key":"rf23_182","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.1010.34517"},{"key":"rf24_183","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.10.1291"},{"key":"rf25_184","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.1.109.33504"},{"key":"rf26_185","doi-asserted-by":"publisher","DOI":"10.1086\/338403"},{"key":"rf27_186","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010302"},{"key":"rf28_187","unstructured":"Leach TS, Lobeck FG, Todd W, Hafkin B. Lack of serotonin syndrome in phase III patients receiving linezolid and a selective serotonin re-uptake inhibitor [abstract 64]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Alexandria, Virginia: Infectious Diseases Society of America, 2000:52."},{"key":"rf29_188","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.43.3.248-a"},{"key":"rf30_189","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.42.5.432"},{"key":"rf31_190","doi-asserted-by":"publisher","DOI":"10.1086\/340710"},{"key":"rf32_191","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04376-2"},{"key":"rf33_192","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05410-1"},{"key":"rf34_193","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200203143461121"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/36\/2\/159\/897910\/36-2-159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T19:24:28Z","timestamp":1503429868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1086\/345744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,1,15]]}},"alternative-id":["10.1086\/345744"],"URL":"https:\/\/doi.org\/10.1086\/345744","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,15]]}}}